1. Home
  2. WIT vs UTHR Comparison

WIT vs UTHR Comparison

Compare WIT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wipro Limited

WIT

Wipro Limited

HOLD

Current Price

$2.05

Market Cap

21.4B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$564.66

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIT
UTHR
Founded
1945
1996
Country
India
United States
Employees
230000
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.4B
25.1B
IPO Year
2000
1999

Fundamental Metrics

Financial Performance
Metric
WIT
UTHR
Price
$2.05
$564.66
Analyst Decision
Buy
Analyst Count
0
14
Target Price
N/A
$567.57
AVG Volume (30 Days)
11.4M
526.3K
Earning Date
04-16-2026
05-06-2026
Dividend Yield
5.39%
N/A
EPS Growth
N/A
13.07
EPS
N/A
27.86
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$10.20
$6.39
Revenue Next Year
$4.98
$14.18
P/E Ratio
$16.59
$20.53
Revenue Growth
N/A
2.38
52 Week Low
$2.01
$272.18
52 Week High
$3.13
$607.89

Technical Indicators

Market Signals
Indicator
WIT
UTHR
Relative Strength Index (RSI) 38.65 52.65
Support Level N/A $464.92
Resistance Level $2.86 $607.89
Average True Range (ATR) 0.07 13.13
MACD -0.01 -3.28
Stochastic Oscillator 12.50 23.72

Price Performance

Historical Comparison
WIT
UTHR

About WIT Wipro Limited

Wipro is a multinational IT services provider based in Bengaluru, India. The company pivoted into the IT space in the 1980s and grew into one of the largest Indian IT consulting companies during the dot-com boom. Nowadays, Wipro leverages its offshore outsourcing model to derive a significant portion of its revenue from North America and Europe.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: